吗替麦考酚酯治疗难治性肾病综合征的疗效观察

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (2): 186-190.

吗替麦考酚酯治疗难治性肾病综合征的疗效观察

黄云剑, 王梓华, 张静波, 陈枫, 赵景宏

第三军医大学新桥医院肾内科, 重庆400037

收稿日期:2008-12-15 修回日期:2009-01-15 出版日期:2009-02-26 发布日期:2020-10-30
通讯作者: 赵景宏, 女, 副教授, 研究方向:肾小球肾炎的发病机制及治疗。Tel:023-68774921 　E-mail:zhaojh73@yahoo.com.cn
作者简介:黄云剑, 男, 副教授, 硕士生导师, 研究方向:肾小球肾炎的发病机制及治疗。Tel:023-68774021 　E-mail:h55769@yahoo.com.cn

Therapeutic effects of mycophenolate mofetil in refractory nephrotic syndrome

HUANG Yun-jian, WANG Zi-hua, ZHANG Jing-bo, CHEN Feng, ZHAO Jing-hong

Department of Nephrology, XinqiaoHospital, Third Military Medical College, Chongqing 400037, China

Received:2008-12-15 Revised:2009-01-15 Online:2009-02-26 Published:2020-10-30

摘要/Abstract

摘要： 目的:探讨吗替麦考酚酯(MMF) 治疗激素抵抗肾病综合征的疗效。方法:选择本院确诊为肾病综合征患者24 例, 经强的松1 mg·kg^-1 ·d^-18 周以上疗效不佳或复发的患者, 其中个别患者还经过环磷酰胺或环孢霉素A 治疗。所有患者均采用MMF 联合小剂量激素治疗, MMF 起始剂量为1.0 ～ 1.5 g/d, 至少3 个月后开始减量, 维持量在0.5 ～ 1.0 g/d, 强的松剂量5 ～ 20 mg/d, 随访时间≥6 个月, 主要观察治疗前后尿蛋白、血清白蛋白、肝功能、肾功能等的变化。结果:患者治疗后尿蛋白由治疗前(3.4 ±1.7) g/d 降至(0.9 ±0.2) g/d, 血清白蛋白由治疗前(19.6 ±5.4) g/L增至(36.1 ±7.7) g/L, 血肌酐由治疗前(105.7 ±6.4) μmol/L 降至(90.1 ± 5.8) μmol/L。20 例(83.3 %) 患者病情缓解, 其中完全缓解15 例(65.2 %), 部分缓解5 例(20.8 %), 无反应4 例(16.6 %)。副作用:胃肠适症状8 例(33.3 %), 细菌性肺炎4 例(16.6 %), 带状疱疹1 例(4.1 %), 轻度肝酶升高3 例(12.5 %)。结论:MMF 联合小剂量激素治疗激素抵抗肾病综合征是有效和安全的, 可成为难治性肾病综合征(refractory nephroticsyndrome, RNS) 的治疗选择。

关键词: 吗替麦考酚酯, 难治性肾病综合征, 治疗

Abstract: AIM: To approach the therapeutic effects of mycophenolate mofetil (MMF) in hormonal resistance nephrotic syndromes.METHODS: Patients were diagnosed as nephrotic syndrome and treated with prednisone at the dose of 1 mg·kg ^-1·d ^-1 for over 8 weeks, and 24 patients with unsatisfactory results or were palindromic were selected, and several patients in the 24 patients had been treated with cyclophosphamide or cyclosporine A.All patients were treated with MMF combined with low dose hormone.The initial dose of MMF was 1.0 -1.5 g/d for 3 months, later the dose were reduced, and the maintenance dose of MMF was 0.5 -1.0 g/d, the dose of prednisone was 5 -20 mg/d, the follow-up visit period more than six months. The changes on urine protein, serum albumin, liver function, renal function were compared before and after treatment.RESULTS: Before and after treatment, urine protein decreased from(3.4 ±1.7) g/d to(0.9 ± 0.2) g/d, serum albumin increased from(19.6 ±5.4) g/L to (36.1 ±7.7) g/L.serum creatinine level decreased from(105.7 ±6.4) μmol/L to (90.1 ±5.8) g/L.20 patients(83.3 %) pathogenetic condition were relieved, 15 patients(65.2 %) were with complete remission.5 patients (20.8 %) were partially recovered, and 4 patients (16.6 %) had no response.The adverse effects were observed, including gastrointestinal events (n =8, 33.3 %), bacterial pneumonia (n =4, 16.6 %), herpes zoster (n =1, 4.1 %), hepatic function mild damage (n =3, 12.5 %).CONCLUSION: It is safe and effective to combine MMF with low dose hormone in treatment of hormonal resistance nephrotic syndrome, which could become a therapeutic option for refractory nephrotic syndrome(RNS).

Key words: mycophenolate mofetil, refractory nephrotic syndrome, treatment

中图分类号:

R692

黄云剑, 王梓华, 张静波, 陈枫, 赵景宏. 吗替麦考酚酯治疗难治性肾病综合征的疗效观察[J]. 中国临床药理学与治疗学, 2009, 14(2): 186-190.

HUANG Yun-jian, WANG Zi-hua, ZHANG Jing-bo, CHEN Feng, ZHAO Jing-hong. Therapeutic effects of mycophenolate mofetil in refractory nephrotic syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 186-190.

参考文献

[1] Hodson EM, Craig JC.Therapies for steroid-resistant nephrotic syndrome[J].Pediatr Nephrol, 2008, 23(9):1391-1394.
[2] Bagga A.Steroid resistant nephrotic syndrome recent developments[J].Indian Pediatr, 2006, 43(1):9-13.
[3] Sepe V, Libetta C, Giuliano MG, et al.Mycophenolate mofetil in primary glomerulopathies [J].Kidney Int, 2008, 73(2):154-162.
[4] Ulinski T, Dubourg L, Said MH, et al.Switch from cyclosporine A to mycophenolate mofetil in nephrotic children [J].Pediatr Nephrol, 2005, 20(4):482-485.
[5] Novak I, Frank R, Vento S, et al.Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome[J].Pediatr Nephrol, 2005, 20(9): 1265-1268.
[6] Okada M, Sugimoto K, Yagi K, et al.Mycophenolate mofetil therapy for children with intractable nephrotic syndrome[J].Pediatr Int, 2007, 49(6):933-937.
[7] Choi MJ, Eustace JA, Gimenez LF, et al.Mycophenolate mofetil treatment for primary glomerular diseases[J].Kidney Int, 2002, 61(3):1098-1114.
[8] Maes BD, Oyen R, Claes K, et al.My cophenolate mofetil in IgA nephropathy:results of a 3-year prospective placebo-controlled randomized study[J].Kidney Int, 2004, 65 (5):1842-1849.
[9] Frisch G, Lin J, Rosenstock J, et al.Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy:a double-blind randomized controlled trial[J].Nephrol Dial Transplant, 2005, 20(10): 2139-2145.
[10] Tang S, Leung JC, Chan LY, et al.Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy[J]. Kidney Int, 2005, 68(2):802-812.
[11] Cattran DC, Wang MM, Appel G, et al.Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis[J].Clin Nephrol, 2004, 62(6):405-411.
[12] Senthil NL, Ganguli A, Rathi M, et al.Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis:a pilot study[J]. Nephrol Dial Transplant, 2008, 23(6):1926-1930.
[13] Montane B, Abitbol C, Chandar J, et al.Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade[J].Pediatr Nephrol, 2003, 18 (8):772-777.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[7]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[8]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[9]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[10]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[11]	张莉, 蔺兴遥, 尚芸, 王强. 冻伤的病理机制及治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 347-354.
[12]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[13]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[14]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.
[15]	党洋斌, 梁宇欣, 王天成. 进行性肌阵挛癫痫相关治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1184-1194.